Outpatient-based fractionated Ifosfamide, Carboplatin, Etoposide (ICE) chemotherapy supported with pegfilgrastim for salvage and stem cell mobilisation in transplant eligible patients with relapsed or refractory diffuse large B-cell lymphoma and Hodgkin lymphoma

This study is for adults with certain types of lymphoma (cancer of the lymphatic system) that have come back or stopped responding to treatment. These include diffuse large B-cell lymphoma and Hodgkin lymphoma. The study is testing a chemotherapy combination called ICE (Ifosfamide, Carboplatin, and Etoposide), given as outpatient treatment over three cycles. Researchers are also studying whether two injections of a drug called pegfilgrastim, given on a single day, can collect enough stem cells from the blood to allow for a stem cell transplant — which is necessary for high-dose curative treatment. You may be eligible if: - You are 18 years of age or older - You have relapsed or refractory diffuse large B-cell non-Hodgkin lymphoma or Hodgkin lymphoma - You are being considered for a stem cell transplant - Your general health status (ECOG performance status) is 0, 1, or 2 - You have a life expectancy of at least 3 months - You are able to give written consent You may NOT be eligible if: - You have already had more than one course of chemotherapy - You have severe heart, liver, breathing, or kidney problems - You are HIV positive - You are pregnant or breastfeeding - You have had a previous stem cell or bone marrow transplant - You have had radiotherapy to more than 20% of your bone marrow - You have had another cancer in the past 5 years (except minor skin cancers or early-stage cervical cancer) Talk to your doctor about whether this trial might be right for you.